Chen G
Department of Orthopedics, First Affiliated Hospital of South-West Medical University, Luzhou, Sichuan Province, China.
Eur Rev Med Pharmacol Sci. 2017 Feb;21(3):490-497.
To explore the relationship between the expression of TAM, survivin and the degree of necrosis of the tumor after cisplatin treatment in osteosarcoma.
The mice model of osteosarcoma S180 were injected with 6 mg/kg/day of cisplatin (observation group) or the same amount of normal saline (control group) for 4 weeks. Mice were sacrificed at days 1, 4, 9, 14, 18, 22 and 28, respectively, 24 h before administration of the drug or saline, and tumor tissues were collected. The size of the tumor samples was measured and the correlation of TAM, survivin expression in osteosarcoma and necrosis degree of tumor tissue after cisplatin treatment was studied using various methods including fluorescence quantitative PCR, enzyme linked immunosorbent assay (ELISA), Western blotting and immunohistochemistry.
Fluorescence quantitative PCR showed that the expression of TAM, survivin mRNA in the control group was significantly higher than that in the observation group. Also, the ELISA monitoring showed that the expression of mice TAM, survivin protein in vivo was significantly lower than TAM, survivin protein expression of mice in vivo in the observation group (2.3 µg/l, 1.6 µg/l) relatively to the control group (9.7 mg/l, 10.3 µg/l). Consistent with the Western blot data, ELISA results showed that the expression of survivin and TAM protein decreased gradually with the prolongation of drug treatment along the time in the observation group. The volume and weight of the tumor in the observation group were significantly less than that of the control group. Additionally, the tumor necrosis of mice in the observation group was more significant, suggesting that the meant of the size of tumor tissue decreased significantly with the extension of the time of drug treatment. Immunohistochemical results showed that the rate of the positive cell of TAM and survivin in the observation group (82.3%) was significantly higher (p<0.05) than that in the control group (19.5%). However, the rate of the positive cell of survivin and TAM gradually declined at the level of the trend with the extension of the time of drug treatment in the observation group.
Cisplatin treatment can inhibit the expression of TAM and survivin in osteosarcoma tissue sand then, promote the necrosis of tumor tissue.
探讨骨肉瘤中TAM、survivin的表达与顺铂治疗后肿瘤坏死程度之间的关系。
将骨肉瘤S180小鼠模型分为两组，分别给予6mg/kg/天的顺铂（观察组）或等量生理盐水（对照组），连续给药4周。分别于给药或给予生理盐水前24小时，在第1、4、9、14、18、22和28天处死小鼠，收集肿瘤组织。测量肿瘤样本大小，并采用荧光定量PCR、酶联免疫吸附测定（ELISA）、蛋白质免疫印迹法和免疫组织化学等多种方法，研究骨肉瘤中TAM、survivin表达与顺铂治疗后肿瘤组织坏死程度的相关性。
荧光定量PCR结果显示，对照组中TAM、survivin mRNA的表达显著高于观察组。此外，ELISA监测显示，与对照组（9.7μg/l、10.3μg/l）相比，观察组小鼠体内TAM、survivin蛋白的表达相对显著降低（2.3μg/l、1.6μg/l）。与蛋白质免疫印迹数据一致，ELISA结果显示，观察组中survivin和TAM蛋白的表达随药物治疗时间的延长而逐渐降低。观察组肿瘤的体积和重量显著小于对照组。此外，观察组小鼠的肿瘤坏死更明显，提示随着药物治疗时间的延长，肿瘤组织大小显著减小。免疫组织化学结果显示，观察组中TAM和survivin的阳性细胞率（82.3%）显著高于对照组（19.5%）（p<0.05）。然而，在观察组中，随着药物治疗时间的延长，survivin和TAM的阳性细胞率呈逐渐下降趋势。
顺铂治疗可抑制骨肉瘤组织中TAM和survivin的表达，进而促进肿瘤组织坏死。
